BioSpace News Archive

Biocept’s patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions

World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.

Novel biofungicide effective on specialty crops for yield-robbing diseases

AMN Healthcare Services, Inc. (NYSE: AMN), healthcare’s leader and innovator in workforce solutions and staffing services, has scheduled a conference call to discuss its fourth quarter and full year 2019 financial results on Thursday, February 13, 2020 at 5:00 p.m. Eastern Time

Digital Tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.

To be ISO 27001 compliant means Epiphany meets the security standards from the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC).

Dr. Obrigkeit brings more than 20 years of experience in medical devices, holding leadership roles internationally for both start-ups and large-scale corporations.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced the results of its Phase 1b clinical trial of LRRK2 inhibitor DNL201 in patients with Parkinson’s disease and its Phase 1 clinical trial of LRRK2 inhibitor DNL151 in healthy volunteers.

Oncology Analytics, a leading technology-enabled service company which provides health plans, providers and patients with an evidence-based, analytics focused approach to utilization management purpose-built for oncology, has announced the appointment of Dr. Peter Bach, director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes to the company’s Board of Directors

The integration of the AMA’s PIN platform with the RedCrow community creates a unique nexus point for health care innovation where health care startups can benefit from greater insight and expert involvement